接受和承诺治疗刺激性肠综合征和炎症性肠病:叙述性综述
Sara H Marchese1, Jessica P Naftaly2, John Pandolfino1
1Division of Gastroenterology & Hepatology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Translational gastroenterology and hepatology
|August 2, 2024
概括
接受和承诺疗法 (ACT) 显示出有希望的症状管理和改善患者生活质量的刺激性肠综合征 (IBS) 和炎症性肠病 (IBD). 建议对强大的设计进行进一步的研究,以确认ACT的确实性.
科学领域:
- 胃肠病学 胃肠病学
- 心理学 心理学 心理学
- 行为医学是一种行为医学.
背景情况:
- 认知行为疗法 (CBT) 是对刺激性肠综合征 (IBS) 和炎症性肠病 (IBD) 的常见治疗方法.
- 接受和承诺疗法 (ACT) 为那些可能无法从CBT中受益的患者提供了替代方法.
- 本综述审查了成人IBS和IBD患者中ACT的证据.
研究的目的:
- 为在IBS或IBD的成年患者中使用ACT提供证据.
- 确定ACT可能有利于IBS或IBD患者的情况.
- 建议这些人群中ACT的未来研究方向.
主要方法:
- 在2023年8月至2024年1月期间进行的文献搜索.
- 搜索的数据库包括谷歌学者,机构图书馆和PubMed.
- 排除标准:非英语研究,儿科群体和不使用完整ACT协议的研究.
主要成果:
- 对IBS的ACT干预 (自助书,研讨会) 显示IBS和情绪症状减少,生活质量改善.
- 针对IBD的三项随机对照试验 (RCT) 发现,ACT在两项研究中减少了压力,抑郁和焦虑症状.
- 有限的研究存在,但结果表明ACT的潜在疗效.
结论:
- 在控制IBS和IBD患者的症状和改善生活质量方面,ACT显示出潜在的有效性.
- 需要通过强大的实验设计进行进一步的研究.
- 未来的研究应该评估在IBS和IBD中ACT有效性的过程和结果措施.
相关概念视频
01:30Irritable Bowel Syndrome III: Medical and Nursing Management
189
Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
189
01:30Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
154
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
154
01:17Irritable Bowel Syndrome I: Introduction
264
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
264
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
331
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
331
01:21Drugs for Treatment of Constipation-Predominant IBS
151
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
151
01:17Drugs for Treatment of Diarrhea-Predominant IBS
156
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
156